Skip to main content
Livermore
Livermore
ZHEN

Braveheart Bio, Inc.

BRVE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002131524

In the last 90 days, Braveheart Bio, Inc. insiders filed 9 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Holders of 5% or more of BRVE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Braveheart Bio, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BRVE
HolderLatest formStakeChangeFirst filedLatest filingFiling
OrbiMed Advisors LLC13D/A13.50%12.2M shares−3.70 ppfrom 17.20%Aug 18, 20262 filingsSep 10, 2026SEC
AH Bio Fund IV, L.P.13D11.40%10.2M sharesNewAug 14, 20261 filingAug 14, 2026SEC
Frazier Life Sciences Public Fund, L.P.13G5.50%4.98M sharesNewAug 14, 20261 filingAug 14, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Braveheart Bio, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BRVE
Filed (ET)FilerFormStakeChangeEvent dateFiling
Sep 10, 20265:07 PM ETOrbiMed Advisors LLCand 2 others13D/A13.50%12.2M shares−3.70 ppfrom 17.20%Sep 8, 2026SEC
Aug 18, 20264:59 PM ETOrbiMed Advisors LLCand 2 others13D17.20%12.2M sharesNewAug 7, 2026SEC
Aug 14, 20264:55 PM ETAH Bio Fund IV, L.P.and 3 others13D11.40%10.2M sharesNewAug 7, 2026SEC
Aug 14, 20264:24 PM ETFrazier Life Sciences Public Fund, L.P.and 8 others13G5.50%4.98M sharesNewAug 7, 2026SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Braveheart Bio, Inc. shares.

No Form 144 notices for Braveheart Bio, Inc. are on file.